Integra LifeSciences
IART
284 hedge funds and large institutions have $3.95B invested in Integra LifeSciences in 2022 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 113 increasing their positions, 95 reducing their positions, and 23 closing their positions.
52% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 23
19% more repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 95
2% more funds holding
Funds holding: 278 → 284 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.79% less ownership
Funds ownership: 89.7% → 87.92% (-1.8%)
16% less capital invested
Capital invested by funds: $4.71B → $3.95B (-$759M)
45% less call options, than puts
Call options by funds: $5.63M | Put options by funds: $10.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$21.2M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$16.8M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$14.9M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$12M |
| 5 |
Two Sigma Investments
New York
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$177M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$43.2M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$10.1M |
| 4 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$7.98M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$4.92M |
IART Hedge Fund Activity: Q2 2022 in Review
284 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q2 2022, worth a combined $3.95B — down 16% from $4.71B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new IART positions and 23 closed out — a net gain of 12 holders — while 113 added to existing stakes and 95 trimmed.
The largest buyer was Two Sigma Advisers, adding an estimated $21.2M. The largest seller was Capital Research Global Investors, cutting an estimated $177M.
- 284 institutional investors held Integra LifeSciences (IART) as of Q2 2022, up from 278 in Q1 2022.
- Funds reported $3.95B of Integra LifeSciences stock for Q2 2022, down 16% quarter-over-quarter.
- 35 funds opened new Integra LifeSciences positions in Q2 2022 and 23 closed out, a net change of +12 holders.
- The largest Integra LifeSciences buyer in Q2 2022 was Two Sigma Advisers, an estimated $21.2M added.
- The largest Integra LifeSciences seller in Q2 2022 was Capital Research Global Investors, an estimated $177M sold.
Based on aggregated 13F filings for Q2 2022.